SCHEMBL26686302

SCHEMBL26686302

CCc1ccccc1NC(=O)Nc1cc(-c2ccc3[nH]nc(N)c3c2)ccn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 9/20 0.46
▸ JAK1 P23458 2/20 0.46
▸ MAPK1 P28482 8/20 0.45
▸ PLK4 O00444 3/20 0.43
▸ AURKB Q96GD4 3/20 0.43
▸ GSK3A P49840 2/20 0.43
▸ DAPK3 O43293 2/20 0.43
▸ DYRK3 O43781 2/20 0.43
▸ ROCK2 O75116 2/20 0.43
▸ MAP4K4 O95819 2/20 0.43
▸ CDK1 P06493 2/20 0.43
▸ RPS6KB1 P23443 2/20 0.43
▸ CDK2 P24941 2/20 0.43
▸ MARK3 P27448 2/20 0.43
▸ TYK2 P29597 2/20 0.43
▸ CLK2 P49760 2/20 0.43
▸ JAK3 P52333 2/20 0.43
▸ LIMK1 P53667 2/20 0.43
▸ CDK5 Q00535 2/20 0.43
▸ PRKCD Q05655 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30633358 1.00 JAK2 (0.46) JAK2JAK1MAPK1PLK4AURKB
SCHEMBL26686360 0.88 KDR (0.52) JAK2JAK1MAPK1MAPTKDR
SCHEMBL30633321 0.88 KDR (0.52) JAK2JAK1MAPK1MAPTKDR
SCHEMBL26686141 0.85 JAK2 (0.45) JAK2JAK1MAPK1DYRK1ACYP3A4
SCHEMBL30633313 0.85 JAK2 (0.45) JAK2JAK1MAPK1DYRK1ACYP3A4
SCHEMBL30633312 0.85 JAK2 (0.45) JAK2JAK1MAPK1DYRK1ASMN1; SMN2
SCHEMBL30633352 0.83 JAK2 (0.56) JAK2JAK1MAPK1PLK4AURKB
SCHEMBL31240315 0.83 MAPK1 (0.56) JAK2MAPK1PLK4AURKBGSK3A
SCHEMBL26685764 0.83 MAPK1 (0.56) JAK2MAPK1PLK4AURKBGSK3A
SCHEMBL26685861 0.83 JAK2 (0.56) JAK2JAK1MAPK1PLK4AURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4705291-A1 IKK-ALPHA INHIBITORS Cancer Research Technology Limited (GB) 2026-03-11 — — EP claimed
US-20250304576-A1 IKK INHIBITORS CANCER RESEARCH TECH LTD (GB) 2025-10-02 — — US claimed
EP-4522597-A1 IKK INHIBITORS Cancer Research Technology Limited (GB) 2025-03-19 — — EP claimed
WO-2024228035-A1 IKK-ALPHA INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-11-07 — — WO claimed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO claimed
EP-4705291-A1 IKK-ALPHA INHIBITORS Cancer Research Technology Limited (GB) 2026-03-11 — — EP disclosed
US-20250304576-A1 IKK INHIBITORS CANCER RESEARCH TECH LTD (GB) 2025-10-02 — — US disclosed
EP-4522597-A1 IKK INHIBITORS Cancer Research Technology Limited (GB) 2025-03-19 — — EP disclosed
WO-2024228035-A1 IKK-ALPHA INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-11-07 — — WO disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304576-A1 IKK INHIBITORS NFKBIA, IKBKE, IKBKB JAK2 207/4885JAK1 95/4885MAPK1 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback